Synonyms: cyclo[Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-D-Pro-Pro-Nle(Bu)-Glu-Thr] | POL-6014 | POL6014
Compound class:
Synthetic organic
Comment: Lonodelestat is a modified cyclic peptide (macrolide) that acts as a selective inhibitor of human neutrophil elastase (hNE). It is being developed by Santhera Pharmaceuticals, under license from its originator Polyphor. In April 2020 Santhera announced a COVID-19 collaboration, in which non-clinical research will be conducted by Cold Spring Harbor Laboratory (CSHL) to further validate hNE as a target and assess lonodelestat as a potential agent for treating COVID-19-related acute respiratory distress syndrome (ARDS).
|
|
Immunopharmacology Comments |
Neutrophil elastase activity is associated with inflammation in the lungs, and its effects are damaging to lung tissue. Inhibiting neutrophil elastase function may minimise tissue destruction and decrease airway inflammation in diseases that are characterised by predominantly neutrophil-mediated inflammation. |